Skip to main content
. 2021 Jun 21;12:691936. doi: 10.3389/fphar.2021.691936

FIGURE 5.

FIGURE 5

Plasma and brain pharmacokinetic performance of formulations. (A): Mean concentration time profiles of Rufinamide obtained following intranasal administration of Rufi-NP-Susp, Rufi-NP-RXG, and Rufi-Susp in plasma; (B): Mean concentration time profiles of Rufinamide obtained following intranasal administration of Rufi-NP-Susp, Rufi-NP-RXG, and Rufi-Susp in the brain. Note: Each data point is a representation of mean ± SD of n = 4 animals for plasma PK, and for brain PK n = 4 animals were used at every time point.